The company met our estimates across lines for FY24; outperformed on sales/Gross Profits (+6.5%/+7.9%) basis but underperformed on EBITDA/adj. PAT (-2.2%/-5.1%) basis in Q4FY24? The company is in an extensive R&D and marketing and promotions mode in order to bring out more NCEs, Consumer Health and biosimilar products to mitigate impact of its key product in the US like gRevlimid going off patent by the beginning of Q4FY26